PURPOSE:

This workshop aims to explore the ripple effect of the European Union’s Joint Clinical Assessment (JCA) on health technology assessment (HTA) in non-EU countries. It will include perspectives from the global market, established HTA markets, and regions where reimbursement decisions often lag behind the EU.

DESCRIPTION:

The EU JCA is at the forefront of discussions within the HTA and payer communities, aiming to enhance efficiency and synergize the evaluation of new treatments across EU countries. Despite uncertainties in its implementation, the JCA's influence is expected to extend globally, as HTA reports often serve as references for agencies and payers worldwide. This workshop aims to highlight the broader impacts of the JCA, such as harmonization of standards, HTA method development, horizon scanning, and collaboration both within and across geographic regions. The panel will explore the complexities, opportunities, and expected changes from an international viewpoint.

Dr. Yeh (chair) will provide an overview of JCA, highlighting the challenges and opportunities of using HTA evidence across borders. Dr. Vidal will discuss how JCA impacts a pharmaceutical company's global support for its country affiliates. Additionally, she will present findings from a recent survey examining the anticipated impact of JCA on 14 non-EU countries. Dr. Shum will offer insights from the perspective of a mature HTA market, detailing how HTA reports from other regions are utilized in Canada and the anticipated effects of JCA. Dr. Lin will share the perspective of an HTA submission reviewer in Taiwan, where reimbursement decisions for new treatments are generally delayed relative to the EU. She will discuss the current utilization of HTA reports from other countries in Taiwan and the potential use of JCA reports.

The workshop will employ live polling for audience input on JCA’s ripple effect, leading to an interactive discussion to conclude the session.